KRSA vs PAHC: stock comparison and AI forecast
Korsana Biosciences, Inc. (KRSA) and Phibro Animal Health Corp (PAHC) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
KRSA Korsana Biosciences, Inc.
- Market Cap
- $1.39B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
PAHC Phibro Animal Health Corp
- Market Cap
- $1.44B
- P/E Ratio
- 14.2x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- KRSA and PAHC have similar market capitalizations ($1.39B and $1.44B).
- PAHC yields 1.35% in dividends; KRSA pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | KRSA | PAHC |
|---|---|---|
| Market Cap | $1.39B | $1.44B |
| P/E Ratio | – | 14.16x |
| P/B Ratio | 3.55x | – |
| Dividend Yield | – | 1.35% |
| EPS | $-4.95 | $2.50 |
| Book Value/Share | $8.57 | – |
| Revenue/Share | – | $37.95 |
| FCF/Share | – | $0.53 |
Profitability & Margins
| Metric | KRSA | PAHC |
|---|---|---|
| ROIC | -1.2% | – |
| Gross Margin | – | 33.8% |
| Operating Margin | -248.8% | 27.8% |
| EBT Margin | -178.3% | 20.2% |
| Tax Rate | – | 26.6% |
Financial Health
| Metric | KRSA | PAHC |
|---|---|---|
| Current Ratio | 10.42x | 3.20x |
| Quick Ratio | – | 1.28x |
| D/E Ratio | 0.12x | – |
| Financial Leverage | 1.18x | – |
| Interest Coverage | – | 1.1x |
| Working Capital | $416M | $649M |
Cash Flow
| Metric | KRSA | PAHC |
|---|---|---|
| Operating Cash Flow | -$52M | $86M |
| Free Cash Flow | – | $22M |
| Capital Spending | – | -$64M |
| OCF Growth YoY | – | 11.6% |
| FCF Growth YoY | – | -54.2% |
| FCF/Sales | – | 1.4% |
| CapEx/Sales | – | 4.2% |
Operational Efficiency
| Metric | KRSA | PAHC |
|---|---|---|
| Receivables Turnover | – | 7.0x |
| Inventory Turnover | – | 1.8x |
| Fixed Assets Turnover | – | 4.1x |
| Days Sales Outstanding | – | 53 days |
| Days Inventory | – | 203 days |
| Payables Period | – | 49 days |
| Cash Conversion Cycle | – | 207 days |
Income Statement
| Metric | KRSA | PAHC |
|---|---|---|
| Total Revenue | – | $1.54B |
| Operating Income | -$5M | $193M |
| R&D Expense | $2M | – |
| SG&A Expense | – | $328M |
| Cost of Goods Sold | – | $1.02B |
Dividend & Shareholder Information
| Metric | KRSA | PAHC |
|---|---|---|
| Dividends Per Share | – | $0.48 |
| Payout Ratio | – | 19.2% |
| Shares Outstanding | 46M | 41M |
| EPS Growth | – | 49.7% |
KRSA vs PAHC: stock comparison and AI forecast
Which is bigger, KRSA or PAHC?
KRSA and PAHC have similar market capitalizations ($1.39B and $1.44B).
Which one does Intratio's AI model rank higher, KRSA or PAHC?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.